Table 2.
Risk of Tumor Recurrence in HCC Patients after RFA.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95%CI) | p value* | HR (95%CI) | p value* | |
| Sex (male/female) | 0.926 (0.706-1.214) | 0.579 | ||
| Age (>60/≤60 years) | 1.738 (1.107-2.728) | 0.016 | 1.625 (1.030-2.565) | 0.037 |
| Performance status (1/0) | 1.542 (0.813-2.925) | 0.184 | ||
| BMI (>25/≤25 kg/m2) | 0.936 (0.692-1.265) | 0.667 | ||
| INR (>1.1/≤1.1) | 1.441 (1.082-1.919) | 0.012 | ||
| Albumin (>3.5/≤3.5 g/dL) | 0.560 (0.424-0.739) | <0.001 | 0.691 (0.515-0.926) | 0.013 |
| Total bilirubin (>1.0/≤1.0 mg/dL) | 1.491 (1.109-2.003) | 0.008 | ||
| AST (>30/≤30 IU/L) | 2.587 (1.654-4.047) | <0.001 | 2.164 (1.361-3.441) | 0.001 |
| ALT (>30/≤30 IU/L) | 1.529 (1.105-2.117) | 0.010 | ||
| Platelet counts (>15×104/≤15×104/μL) | 0.691 (0.486-0.984) | 0.040 | ||
| Creatinine (>0.8/≤0.8 mg/dL) | 1.039 (0.785-1.375) | 0.790 | ||
| Child-Pugh classification (B/A) | 1.287 (0.934-1.774) | 0.123 | ||
| MELD | 1.063 (1.011-1.118) | 0.016 | ||
| Anti-HCV (+/-) | 1.535 (1.097-2.148) | 0.012 | ||
| HBsAg (+/-) | 0.469 (0.266-0.824) | 0.008 | ||
| AFP (>50/≤50 ng/mL) | 1.628 (1.197-2.214) | 0.002 | 1.400 (1.022-1.919) | 0.036 |
| DCP (>400/≤400 mAU/mL) | 2.274 (1.117-4.626) | 0.023 | ||
| No. of nodules (2/1) | 1.491 (1.052-2.114) | 0.025 | 1.384 (0.974-1.968) | 0.070 |
| No. of nodules (3/1) | 2.398 (1.327-4.332) | 0.004 | 1.900 (1.047-3.449) | 0.035 |
| Size of largest tumor (mm) | 1.034 (1.007-1.061) | 0.012 | 1.032 (1.006-1.059) | 0.016 |
*p values were determined with Cox proportional hazards regression models. p<0.05 indicated a significant difference.
HCC: hepatocellular carcinoma, HR: hazard ratio, CI: confidence intervals, RFA: radiofrequency ablation, BMI: body mass index, INR: international normalized ratio, AST: aspartate aminotransferase, ALT: alanine aminotransferase, MELD: model for end-stage liver disease, Anti-HCV: antibody to hepatitis C virus, HBsAg: hepatitis B surface antigen, AFP: alpha-fetoprotein, DCP: des-gamma-carboxy prothrombin